Medichem at a glance
1972
Foundation
+450
Employees
+60
Countries
+600
Worldwide customers
10%
of the our turnover invested in R&D
Vertically
integrated model
About us?
European quality
Founded in 1972, we are a leading European pharmaceutical company with over five decades of expertise in delivering high-quality solutions to the global generics market. We specialize in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs), serving both international generics leaders and partners seeking exclusive, long-term collaborations.
As the only manufacturer and supplier of Chlorhexidine in the continent, we hold a unique position in the market, reinforcing our commitment to supply security and European manufacturing excellence.
We're as integrated as it gets
We operate as a fully integrated Contract Development and Manufacturing Organization (CDMO). We specialize in oral dosage forms, produced in our manufacturing site in Malta, and injectable products, manufactured in our fill and finish sterile production plant in Asturias, Spain.
Also, as part of the B Corp community, we uphold the highest standards of quality, operational performance, and social and environmental responsibility.
Where are we?
A global company based in Spain that serves 600 customers worldwide.
Worldwide presence
Headquarters
Barcelona
Commercial offices
New York Nanjing
R&D centres
Barcelona Girona Asturias Malta
Manufactoring plants
Girona Asturias Malta
Medichem Solutions
Asturias
We operate with a strong international customer base and supply products to more than 60 countries, including the United States, India, China and within Europe, while consolidating alliances with strategic partners.
Our R&D centers and manufacturing plants are located in Spain and Malta, while our commercial offices are located in Spain, China and the USA.
The success of our international expansion is based on continuous innovation and R&D investment, which guarantees a product adapted to the particularities of each country that meets all regulatory requirements.
Innovation
Innovation and Intellectual Property drive us.
We are at the forefront of innovation, and as R&D is the root of Medichem´s strategy and success, we invest 10% of the turnover in R&D and we have 20 projects in R&D pipeline.
At Medichem, we provide guidance on intellectual property. We own 80 patents and patent applications. Also, our plants in Malta allow PIV and first-to-market opportunities.
At the forefront of innovation
Company turnover dedicated to R&D
Projects in R&D pipeline
Company profile
Should you need more information on our products under development, please contact us.
